Pathogenesis of myeloma bone disease

Journal of Cellular Biochemistry

Volumn 109, Issue 2, 2010, Pages 283-291

  Roodman, G David ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Bone disease; Metastasis; Myeloma

Indexed keywords

ACTIVIN A INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR1 ANTAGONIST; CYTOKINE; DENOSUMAB; DEXAMETHASONE; DICKKOPF 1 PROTEIN INHIBITOR; LENALIDOMIDE; POMALIDOMIDE; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

BONE ATROPHY; BONE DESTRUCTION; BONE DISEASE; BONE METASTASIS; CANCER GROWTH; CLINICAL TRIAL; DISEASE SEVERITY; HUMAN; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; MYELOMA BONE DISEASE; MYELOMA CELL; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOPOROSIS; PATHOGENESIS; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; REVIEW; STROMA CELL; TUMOR VASCULARIZATION;

ANIMALS; BONE MARROW CELLS; BONE RESORPTION; CELL ADHESION; CELL COMMUNICATION; HUMANS; MICE; MULTIPLE MYELOMA; NEOPLASM METASTASIS; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; OSTEOLYSIS; SIGNAL TRANSDUCTION; STROMAL CELLS;

EID: 74949100969     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22403     Document Type: Review

References (86)

1. Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, Hashimoto T, Kido S, Oshima T, Shibata H, Ozaki S, Inoue D, Matsumoto T. 2004. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: A vicious cycle between bone destruction and myeloma expansion. Blood 104:2484-2491.
2. Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, Pitsillides CM, Spencer JA, Kimlinger T, Ghobrial JM, Jia X, Lu G, Timm M, Kumar A, Cote D, Veilleux I, Hedin KE, Roodman GD, Witzig TE, Kung AL, Hideshima T, Anderson KC, Lin CP, Ghobrial IM. 2007. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 109:2708-2717.
3. Alsina M, Boyce B, Devlin RD, Anderson JL, Craig F, Mundy GR, Roodman GD. 1996. Development of an in vivo model of human multiple myeloma bone disease. Blood 87:1495-1501.
4. Anderson G, Gries M, Kurihara N, Honjo T, Anderson J, Donnenberg V, Donnenberg A, Ghobrial I, Mapara MY, Stirling D, Roodman D, Lentzsch S. 2006. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 107:3098-3105.
5. Barille-Nion S, Bataille R. 2003. New insights in myeloma-induced osteolysis. Leuk Lymphoma 44:1463-1467.
6. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M, Blacklock H, Bell R, Simeone JF, Reitsma DJ, Heffernan M, Seaman J, Knight RD. 1998. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 16:593-602.
7. Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M, Holloway D, Peterson MC, Bekker PJ. 2006. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12:1221-1228.
8. Boyle WJ, Simonet WS, Lacey DL. 2003. Osteoclast differentiation and activation. Nature 423:337-342.
9. Breitkreutz I, Raab MS, Vallet S, Hideshima T, Raje N, Mitsiades C, Chauhan D, Okawa Y, Munshi NC, Richardson PG, Anderson KC. 2008. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 22:1925-1932.
10. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS. 1998. Osteoprotegerindeficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260-1268.
11. Cackowski FC, Anderson JL, Patrene KD, Choksi RJ, Shapiro SD, Windle JJ, Blair HC, Roodman GD. 2009. Osteoclasts are important for bone angiogenesis. Blood [Epub ahead of print].
12. Choi SJ, Oba Y, Gazitt Y, Alsina M, Cruz J, Anderson J, Roodman GD. 2001. Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. J Clin Invest 108:1833-1841.
13. Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, Saad F, Zheng M, Hei YJ, Seaman J, Cook R. 2005. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23:4925-4935.
14. Diamond T, Levy S, Day P, Barbagallo S, Manoharan A, Kwan YK. 1997. Biochemical, histomorphometric and densitometric changes in patients with multiple myeloma: Effects of glucocorticoid therapy and disease activity. Br J Haematol 97:641-648.
15. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, Daro E, Smith J, Tometsko ME, Maliszewski CR, Armstrong A, Shen V, Bain S, Cosman D, Anderson D, Morrissey PJ, Peschon JJ, Schuh J. 1999. RANK is essential for osteoclast and lymph node development. Genes Dev 13:2412-2424.
16. D'Souza S, Del Prete D, Yu S, Xiao G, Roodman GD. 2009a. Multiple myeloma induces Gfi-1 expression in stromal cells resulting in suppression of osteoblast differentiation: "American Society of Bone and Mineral." Denver, CO: (Abstract).
17. D'Souza S, Shiozawa Y, Galson DL, Taichman R, Roodman GD. 2009b. Annexin II and Annexin II receptor interactions enhance multiple myeloma growth in the bone marrow microenvironment.: "The IX International Meeting on Cancer Induced Bone Disease." Arlington, VA: (Abstract).
18. Edwards CM, Zhuang J, Mundy GR. 2008. The pathogenesis of the bone disease of multiple myeloma. Bone 42:1007-1013.
19. Ehrlich LA, Chung HY, Ghobrial I, Choi SJ, Morandi F, Colla S, Rizzoli V, Roodman GD, Giuliani N. 2005. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood 106:1407-1414.
20. Franceschi RT, Xiao G. 2003. Regulation of the osteoblast-specific transcription factor, Runx2: Responsiveness to multiple signal transduction pathways. J Cell Biochem 88:446-454.
21. Garrett IR, Chen D, Gutierrez G, Zhao M, Escobedo A, Rossini G, Harris SE, Gallwitz W, Kim KB, Hu S, Crews CM, Mundy GR. 2003. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 111:1771-1782.
22. Geetha T, Wooten MW. 2002. Structure and functional properties of the ubiquitin binding protein p62. FEBS Lett 512:19-24.
23. Gilbert L, He X, Farmer P, Rubin J, Drissi H, van Wijnen AJ, Lian JB, Stein GS, Nanes MS. 2002. Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha. J Biol Chem 277:2695-2701.
24. Giuliani N, Colla S, Morandi F, Lazzaretti M, Sala R, Bonomini S, Grano M, Colucci S, Svaldi M, Rizzoli V. 2005. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 106:2472-2483.
25. Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Bonomini S, Crugnola M, Mancini C, Martella E, Ferrari L, Tabilio A, Rizzoli V. 2007. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 110:334-338.
26. Han JH, Choi SJ, Kurihara N, Koide M, Oba Y, Roodman GD. 2001. Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood 97:3349-3353.
27. Hashimoto T, Abe M, Oshima T, Shibata H, Ozaki S, Inoue D, Matsumoto T. 2004. Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma. Br J Haematol 125:38-41.
28. Heider U, Kaiser M, Muller C, Jakob C, Zavrski I, Schulz CO, Fleissner C, Hecht M, Sezer O. 2006. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol 77:233-238.
29. Hiruma Y, Honjo T, Jelinek D, Windle JJ, Shin J, Roodman GD, Kurihara N. 2009. Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation. Blood 113:4894-4902.
30. Hjorth-Hansen H, Seifert MF, Borset M, Aarset H, Ostlie A, Sundan A, Waage A. 1999. Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. J Bone Miner Res 14:256-263.
31. Hofbauer LC, Heufelder AE. 1998. Osteoprotegerin and its cognate ligand: A new paradigm of osteoclastogenesis. Eur J Endocrinol 139:152-154.
32. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ. 1999. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96:3540-3545.
33. Kobayashi T, Kronenberg H. 2005. Minireview: Transcriptional regulation in development of bone. Endocrinology 146:1012-1017.
34. Kollet O, Dar A, Lapidot T. 2007. The multiple roles of osteoclasts in host defense: Bone remodeling and hematopoietic stem cell mobilization. Annu Rev Immunol 25:51-69.
35. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM. 1999. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323.
36. Kropff M, Bisping G, Wenning D, Berdel WE, Kienast J. 2006. Proteasome inhibition in multiple myeloma. Eur J Cancer 42:1623-1639.
37. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
38. Lee YH, Ko J, Joung I, Kim JH, Shin J. 1998. Immediate early response of the p62 gene encoding a non-proteasomal multiubiquitin chain binding protein. FEBS Lett 438:297-300.
39. Lee JW, Chung HY, Ehrlich LA, Jelinek DF, Callander NS, Roodman GD, Choi SJ. 2004. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 103:2308-2315.
40. Lee SK, Kalinowski JF, Jacquin C, Adams DJ, Gronowicz G, Lorenzo JA. 2006. Interleukin-7 influences osteoclast function in vivo but is not a critical factor in ovariectomy-induced bone loss. J Bone Miner Res 21:695-702.
41. Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, McCabe S, Elliott R, Scully S, Van G, Kaufman S, Juan SC, Sun Y, Tarpley J, Martin L, Christensen K, McCabe J, Kostenuik P, Hsu H, Fletcher F, Dunstan CR, Lacey DL, Boyle WJ. 2000. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 97:1566-1571.
42. Li B, Shi M, Li J, Zhang H, Chen B, Chen L, Gao W, Giuliani N, Zhao RC. 2007. Elevated tumor necrosis factor-alpha suppresses TAZ expression and impairs osteogenic potential of Flk-1+ mesenchymal stem cells in patients with multiple myeloma. Stem Cells Dev 16:921-930.
43. Lu X, Gilbert L, He X, Rubin J, Nanes MS. 2006. Transcriptional regulation of the osterix (Osx, Sp7) promoter by tumor necrosis factor identifies disparate effects of mitogen-activated protein kinase and NF kappa B pathways. J Biol Chem 281:6297-6306.
44. Magrangeas F, Nasser V, Avet-Loiseau H, Loriod B, Decaux O, Granjeaud S, Bertucci F, Birnbaum D, Nguyen C, Harousseau JL, Bataille R, Houlgatte R, Minvielle S. 2003. Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood 101:4998-5006.
45. Masih-Khan E, Trudel S, Heise C, Li Z, Paterson J, Nadeem V, Wei E, Roodman D, Claudio JO, Bergsagel PL, Stewart AK. 2006. MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma. Blood 108:3465-3471.
46. Melton LJ III, Kyle RA, Achenbach SJ, Oberg AL, Rajkumar SV. 2005. Fracture risk with multiple myeloma: A population-based study. J Bone Miner Res 20:487-493.
47. Mukai T, Otsuka F, Otani H, Yamashita M, Takasugi K, Inagaki K, Yamamura M, Makino H. 2007. TNF-alpha inhibits BMP-induced osteoblast differentiation through activating SAPK/JNK signaling. Biochem Biophys Res Commun 356:1004-1010.
48. Muller G, Ayoub M, Storz P, Rennecke J, Fabbro D, Pfizenmaier K. 1995. PKC zeta is a molecular switch in signal transduction of TNF-alpha, bifunctionally regulated by ceramide and arachidonic acid. EMBO J 14:1961-1969.
49. Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K, Morinaga T, Higashio K. 1998. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 253:395-400.
50. Nefedova Y, Cheng P, Alsina M, Dalton WS, Gabrilovich DI. 2004. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood 103:3503-3510.
51. Nguyen AN, Stebbins EG, Henson M, O'Young G, Choi SJ, Quon D, Damm D, Reddy M, Ma JY, Haghnazari E, Kapoun AM, Medicherla S, Protter A, Schreiner GF, Kurihara N, Anderson J, Roodman GD, Navas TA, Higgins LS. 2006. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. Exp Cell Res 312:1909-1923.
52. Nimmanapalli R, Gerbino E, Dalton WS, Gandhi V, Alsina M. 2008. HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma. Br J Haematol 142:551-561.
53. Oyajobi BO, Garrett IR, Gupta A, Flores A, Esparza J, Munoz S, Zhao M, Mundy GR. 2007. Stimulation of new bone formation by the proteasome inhibitor, bortezomib: Implications for myeloma bone disease. Br J Haematol 139:434-438.
54. Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, Michaeli J, Epstein J, Choi Y. 2001. Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 98:11581-11586.
55. Raaijmakers MH, Scadden DT. 2008. Evolving concepts on the microenvironmental niche for hematopoietic stem cells. Curr Opin Hematol 15:301-306.
56. Roodman GD. 2003. Role of stromal-derived cytokines and growth factors in bone metastasis. Cancer 97(3 Suppl):733-738.
57. Roodman GD. 2004. Pathogenesis of myeloma bone disease. Blood Cells Mol Dis 32:290-292.
58. Roodman GD. 2007. Treatment strategies for bone disease. Bone Marrow Transplant 40:1139-1146.
59. Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. 2007. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 110:1860-1867.
60. Sanchez P, De Carcer G, Sandoval IV, Moscat J, Diaz-Meco MT. 1998. Localization of atypical protein kinase C isoforms into lysosome-targeted endosomes through interaction with p62. Mol Cell Biol 18:3069-3080.
61. Sanz L, Sanchez P, Lallena MJ, Diaz-Meco MT, Moscat J. 1999. The interaction of p62 with RIP links the atypical PKCs to NF-kappaB activation. EMBO J 18:3044-3053.
62. Sanz L, Diaz-Meco MT, Nakano H, Moscat J. 2000. The atypical PKCinteracting protein p62 channels NF-kappaB activation by the IL-1-TRAF6 pathway. EMBO J 19:1576-1586.
63. Schulman KL, Kohles J. 2007. Economic burden of metastatic bone disease in the United States. Cancer 109:2334-2342.
64. Shiozawa Y, Havens AM, Jung Y, Ziegler AM, Pedersen EA, Wang J, Lu G, Roodman GD, Loberg RD, Pienta KJ, Taichman RS. 2008. Annexin II/Annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer. J Cell Biochem 370:370-380.
65. Silvestris F, Cafforio P, Calvani N, Dammacco F. 2004. Impaired osteoblastogenesis in myeloma bone disease: Role of upregulated apoptosis by cytokines and malignant plasma cells. Br J Haematol 126:475-486.
66. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. 1997. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89:309-319.
67. Taichman RS. 2005. Blood and bone: Two tissues whose fates are intertwined to create the hematopoietic stem-cell niche. Blood 105:2631-2639.
68. Tan SD, Kuijpers-Jagtman AM, Semeins CM, Bronckers AL, Maltha JC, Von den Hoff JW, Everts V, Klein-Nulend J. 2006. Fluid shear stress inhibits TNFalpha-induced osteocyte apoptosis. J Dent Res 85:905-909.
69. Tanaka Y, Abe M, Hiasa M, Oda A, Amou H, Nakano A, Takeuchi K, Kitazoe K, Kido S, Inoue D, Moriyama K, Hashimoto T, Ozaki S, Matsumoto T. 2007. Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: A role for vascular endothelial cell growth factor and osteopontin. Clin Cancer Res 13:816-823.
70. Taube T, Beneton MN, McCloskey EV, Rogers S, Greaves M, Kanis JA. 1992. Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol 49:192-198.
71. Terpos E, Politou M, Szydlo R, Goldman JM, Apperley JF, Rahemtulla A. 2003a. Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br J Haematol 123:106-109.
72. Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J, Viniou N, Yataganas X, Goldman JM, Rahemtulla A. 2003b. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: Proposal for a novel prognostic index. Blood 102:1064-1069.
73. Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A, Pouli A, Katodritou E, Verrou E, Vervessou EC, Dimopoulos MA, Croucher PI. 2006. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 135:688-692.
74. Thirunavukkarasu K, Halladay DL, Miles RR, Yang X, Galvin RJ, Chandrasekhar S, Martin TJ, Onyia JE. 2000. The osteoblast-specific transcription factor Cbfa1 contributes to the expression of osteoprotegerin, a potent inhibitor of osteoclast differentiation and function. J Biol Chem 275:25163-25172.
75. Toraldo G, Roggia C, Qian WP, Pacifici R, Weitzmann MN. 2003. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc Natl Acad Sci USA 100:125-130.
76. Tsukii K, Shima N, Mochizuki S, Yamaguchi K, Kinosaki M, Yano K, Shibata O, Udagawa N, Yasuda H, Suda T, Higashio K. 1998. Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. Biochem Biophys Res Commun 246:337-341.
77. Vallet S, Mukherjee S, Vaghela N, Hideshima T, Pozzi S, Santo L, Yan H, Cirstea D, Seehra J, Scadden D, Anderson K, Raje N. 2008. Effects of RAP-011, a soluble activin receptor, on multiple myeloma (MM) via targeting the microenvironment. AACR Meeting: Abstract #1521.
78. Vanderkerken K, Medicherla S, Coulton L, Van Camp B, Protter A, Higgins L, Menu E, Croucher PI. 2006. Inhibition of p38a MAPK reduces tumor burden, prevents the development;1; of myeloma bone disease, and increases survival in the 5T2 and5T33 murine models of myeloma. Blood 108:981a.
79. Vessella RL, Pantel K, Mohla S. 2007. Tumor cell dormancy: An NCI workshop report. Cancer Biol Ther 6:1496-1504.
80. Vij R, Horvath N, Spencer A, Taylor K, Saroj V, Smith J, Qian Y, Jun S. 2007. An open label phase 2 trial of Denosumab in the treatment of relapsed or plateau-phase myeloma. Blood 118:1054A.
81. Weitzmann MN, Roggia C, Toraldo G, Weitzmann L, Pacifici R. 2002. Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency. J Clin Invest 110:1643-1650.
82. Wooten MW, Seibenhener ML, Mamidipudi V, Diaz-Meco MT, Barker PA, Moscat J. 2001. The atypical protein kinase C-interacting protein p62 is a scaffold for NF-kappaB activation by nerve growth factor. J Biol Chem 276:7709-7712.
83. Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J. 2002. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 116:278-290.
84. Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD, Jr. 2007. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 109:2106-2111.
85. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. 1998. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602.
86. Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, Burns MJ, Kang SH, Yaccoby S, Najarian K, Richardson P, Sonneveld P, Tricot G. 2005. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 131:71-73.